Genome editing approaches to β-hemoglobinopathies

Area of Science:

• Genetics
• Molecular Biology
• Hematology

Background:

• β-hemoglobinopathies are common genetic disorders affecting adult hemoglobin (HbA) production.
• Current lentiviral vector gene therapy shows promise but often has insufficient therapeutic gene expression for severe cases.
• Genome editing presents a novel therapeutic avenue for β-hemoglobinopathies.

Purpose of the Study:

• To review genome editing tools for treating β-hemoglobinopathies.
• To discuss the application of these tools in developing therapeutic strategies.
• To highlight ongoing clinical trials utilizing genome editing.

Main Methods:

• Utilizing double-strand break (DSB)-inducing nucleases like ZFNs, TALENs, and CRISPR-Cas9.
• Employing DSB-free genome editing tools such as base and prime editing.
• Directly correcting disease-causing mutations or reactivating fetal hemoglobin (HbF) expression.

Main Results:

• Genome editing enables precise modification of the β-globin locus.
• Successful restoration of HbA production or HbF reactivation has been demonstrated.
• These approaches aim to provide a curative treatment for sickle cell disease and β-thalassemia.

Conclusions:

• Genome editing technologies hold significant potential for curing β-hemoglobinopathies.
• Various genome editing strategies are being explored in clinical trials.
• The development of advanced genome editing tools offers new hope for patients.